Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 2/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 5/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | USP5 | P45974 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996980 | 0.91 | CPT1A (0.42) | CPT1ASMYD3NAMPTRORCUSP5 | |
| SCHEMBL2003304 | 0.91 | CPT1A (0.47) | CPT1ARORCL3MBTL1NPC1HPGDS | |
| SCHEMBL2002310 | 0.90 | CPT1A (0.47) | CPT1ANAMPTRORCL3MBTL1HPGDS | |
| SCHEMBL2001296 | 0.89 | CPT1A (0.47) | CPT1ARORCNPC1HPGDS | |
| SCHEMBL2002514 | 0.89 | CPT1A (0.45) | CPT1ARORCNPC1ALDH1A1HPGDS | |
| SCHEMBL1998105 | 0.89 | CPT1A (0.45) | CPT1ARORCNPC1ALDH1A1HPGDS | |
| SCHEMBL2001377 | 0.87 | CPT1A (0.44) | CPT1ANAMPTRORCHPGDS | |
| SCHEMBL2005066 | 0.86 | CPT1A (0.42) | CPT1ASMYD3NAMPTUSP5L3MBTL3 | |
| SCHEMBL2006076 | 0.86 | CPT1A (0.47) | CPT1ANAMPTRORCHPGDS | |
| SCHEMBL1998249 | 0.85 | CPT1A (0.46) | CPT1ASMYD3RORCNPC1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | CPT1A 3067/4885SMYD3 3096/4885NAMPT 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.